Roth Capital upgrades Synta Pharmaceuticals (SNTA) from Hold to Buy. Price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE